Discontinuation Rate of Nevirapine-Based Highly Active Antiretroviral Therapy

Abstract

Get full access to this article

View all access options for this article.

References

Podzamczer

, Tiraboschi

, Mallolas

et al. CD4 response, lipid changes, liver outcome in 506 patients receiving nevirapine-based regimens for a median of 9 years. Tenth International Congress on Drug Therapy in HIV Infection, Glasgow, UK, November 7–11, 2010.

Parienti

, Peytavin

. Nevirapine once daily: Pharmacology, metabolic profile and efficacy data of the new extended-release formulation. Expert Opinion Drug MetabToxicol, 2011; 7:495–503.